Bulbocodin D ameliorate cognitive impairment in APP/PS1 transgenic mice by modulating amyloid-beta burden, oxidative status and neuroinflammation

ConclusionIn summary, the present study provides preclinical evidence that oral bulbocodin D can reduce AD pathology.
Source: Psychopharmacology - Category: Psychiatry Source Type: research